Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Johnson & Johnson Stock Research

JNJ

162.16USD-0.75(-0.46%)Delayedas of 21 Sep 2023, 12:04 pm
Watchlist

Market Summary

USD162.16-0.75
Delayedas of 21 Sep 2023, 12:04 pm
-0.46%

JNJ Stock Price

JNJ RSI Chart

JNJ Valuation

Market Cap

423.3B

Price/Earnings (Trailing)

32.43

Price/Sales (Trailing)

4.33

EV/EBITDA

16.68

Price/Free Cashflow

29.1

JNJ Price/Sales (Trailing)

JNJ Profitability

EBT Margin

15.71%

Return on Equity

17.95%

Return on Assets

6.49%

Free Cashflow Yield

3.44%

JNJ Fundamentals

JNJ Revenue

Revenue (TTM)

97.8B

Revenue Y/Y

6.29%

Revenue Q/Q

3.17%

JNJ Earnings

Earnings (TTM)

13.1B

Earnings Y/Y

6.86%

Earnings Q/Q

7.7K%

Price Action

52 Week Range

150.71179.75
(Low)(High)

Last 7 days

-0.7%

Last 30 days

-2.6%

Last 90 days

-1.6%

Trailing 12 Months

0.1%

JNJ Financial Health

Current Ratio

1.07

JNJ Investor Care

Dividend Yield

2.81%

Dividend/Share (TTM)

4.58

Buy Backs (1Y)

1.19%

Diluted EPS (TTM)

4.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for JNJ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-23
McEvoy Ashley
back to issuer
-
-
-2,787
evp, ww chair, medtech
2023-08-23
Duato Joaquin
back to issuer
-
-
-11,035
ceo and chairman of the board
2023-08-23
Fasolo Peter
back to issuer
-
-
-232
exec vp, chief hr officer
2023-08-23
Wolk Joseph J
back to issuer
-
-
-67.00
exec vp, cfo
2023-08-23
Hait William
back to issuer
-
-
-696
see remarks
2023-07-26
Hait William
acquired
1,329,290
90.44
14,698
see remarks
2023-07-26
Hait William
sold
-2,528,060
172
-14,698
see remarks
2023-07-25
Fasolo Peter
sold
-3,406,500
170
-20,000
exec vp, chief hr officer
2023-06-12
Wengel Kathryn E
sold
-1,994,400
160
-12,465
evp, chief to and risk officer
2023-05-24
Wolk Joseph J
gifted
-
-
-55.00
exec vp, cfo

1–10 of 50

Which funds bought or sold JNJ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-8.06
-127,783
6,893,340
2.89%
2023-09-18
CAPE ANN SAVINGS BANK
reduced
-0.34
211,425
3,502,130
2.33%
2023-09-18
WASHINGTON CAPITAL MANAGEMENT, INC
reduced
-3.42
7,083
233,383
0.20%
2023-09-15
CJM Wealth Advisers, Ltd.
added
0.06
38,552
601,992
0.31%
2023-09-14
Proquility Private Wealth Partners, LLC
added
2.11
246,508
2,971,830
1.16%
2023-09-14
IMS Capital Management
added
1.23
162,886
2,172,620
1.21%
2023-09-13
CGC Financial Services, LLC
new
-
409,993
409,993
0.27%
2023-09-13
AWM CAPITAL, LLC
reduced
-1.7
21,379
450,062
0.11%
2023-09-12
DCM Advisors, LLC
unchanged
-
33,464
526,519
0.23%
2023-09-12
Prosperity Financial Group, Inc.
reduced
-11.1
-34,103
638,907
0.56%

1–10 of 48

Latest Funds Activity

Are funds buying JNJ calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JNJ
No. of Funds

Schedule 13G FIlings of Johnson & Johnson

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.44%
246,826,621
SC 13G/A
Jan 31, 2023
blackrock inc.
7.6%
198,802,769
SC 13G/A
Feb 14, 2022
state street corp
5.51%
144,996,127
SC 13G/A
Feb 10, 2022
vanguard group inc
8.92%
234,782,632
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
200,021,352
SC 13G/A
Feb 12, 2021
state street corp
5.47%
144,029,634
SC 13G
Feb 10, 2021
vanguard group inc
8.66%
227,946,104
SC 13G/A
Jan 29, 2021
blackrock inc.
7.2%
188,510,542
SC 13G/A
Feb 13, 2020
state street corp
5.77%
151,867,233
SC 13G
Feb 12, 2020
vanguard group inc
8.67%
228,297,775
SC 13G/A

Recent SEC filings of Johnson & Johnson

View All Filings
Date Filed Form Type Document
Sep 11, 2023
4
Insider Trading
Aug 30, 2023
8-K
Current Report
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
4
Insider Trading
Aug 25, 2023
8-K
Current Report
Aug 23, 2023
425
Prospectus Filed

JNJ Fair Value

Loading...

Peers (Alternatives to Johnson & Johnson)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
512.5B
29.5B
3.56% 89.32%
78.88
17.36
1.53% 14.16%
423.3B
97.8B
-2.65% 0.10%
32.43
4.33
2.29% -28.92%
272.8B
58.3B
-2.13% 26.48%
17.88
4.63
2.00% -81.24%
189.8B
77.9B
-9.16% -24.26%
8.84
2.44
-23.04% -26.74%
150.1B
45.2B
-5.06% -15.06%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.75% 544.26%
-74.04
4.1K
-86.94% 71.24%
4.5B
4.6B
-11.49% -16.32%
-66.69
0.98
6.60% 42.04%
SMALL-CAP
1.9B
627.1M
-7.75% -1.79%
-1.34
3.1
-0.20% -204.67%
1.5B
634.0M
-11.88% -19.94%
34.62
2.37
0.62% -24.59%
832.3M
244.3M
-4.13% 4.68%
4.22
3.41
-39.50% -4.99%
830.8M
109.5M
21.79% -27.57%
-5.79
7.59
-2.66% -32.13%
480.0M
453.3M
110.37% -71.69%
-0.39
1.06
-16.04% 55.90%
479.1M
31.2M
-7.77% -52.62%
-4.55
15.37
407.54% -26.47%
269.4M
54.6M
-13.04% -44.44%
-2.97
4.93
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Johnson & Johnson News

Defense World
Johnson & Johnson (NYSE:JNJ) Stock Holdings Reduced by DNB ....
Defense World,
7 hours ago
InvestorsObserver
The Coin Republic
Zacks Investment Research
InvestorsObserver
The Coin Republic
InvestorsObserver
Investor's Business Daily
J&J Stock Roars Higher As Small Drugs Drive Big Beats.
Investor's Business Daily,
2 months ago
The Coin Republic

Returns for JNJ

Cumulative Returns on JNJ

8.9%


10-Year Cumulative Returns

7.2%


7-Year Cumulative Returns

5.1%


5-Year Cumulative Returns

5.2%


3-Year Cumulative Returns

Risks for JNJ

What is the probability of a big loss on JNJ?

17.7%


Probability that Johnson & Johnson stock will be more than 20% underwater in next one year

0%


Probability that Johnson & Johnson stock will be more than 30% underwater in next one year.

0%


Probability that Johnson & Johnson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JNJ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Johnson & Johnson was unfortunately bought at previous high price.

Drawdowns

Financials for Johnson & Johnson

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.6%97,77396,26394,94396,04195,58894,88093,77591,44689,19084,21482,58480,85680,50382,72982,05981,70681,32581,59381,58181,38280,684
Gross Profit1.9%65,59464,37763,85464,76264,86664,49063,92061,73259,75455,78654,15753,10952,86154,72654,50354,32354,22054,50154,49053,99352,959
  S&GA Expenses1.8%25,40424,96524,76525,40725,31825,16524,65923,96223,39322,31322,08421,66621,60922,16222,17822,13022,29922,49622,54022,59422,474
EBITDA-100.0%-22,68828,97129,56027,68528,60430,34927,28427,86425,03423,92926,37423,53326,65124,655------
EBITDA Margin-100.0%-0.24*0.31*0.31*0.29*0.30*0.32*0.30*0.31*0.30*0.29*0.33*0.29*0.32*0.30*------
Interest Expenses64.0%7894812761591281301832102342392011992032413184836788481,0051,0291,015
Earnings Before Taxes6.1%16,04815,12621,72522,36020,38721,20922,77619,58720,13917,41716,49719,06816,31419,41517,32816,23219,00816,94017,99917,43717,804
EBT Margin-100.0%-0.16*0.23*0.23*0.21*0.22*0.24*0.21*0.23*0.21*0.20*0.24*0.20*0.23*0.21*------
Net Income2.6%13,05412,72417,94119,15718,36619,83020,87817,88017,76715,11514,71416,98615,18517,16615,11914,15116,33214,67915,2971,5421,372
Net Income Margin-100.0%-0.13*0.19*0.20*0.19*0.21*0.22*0.20*0.20*0.18*0.18*0.21*0.19*0.21*0.18*------
Free Cashflow-100.0%-16,20717,18517,73919,95019,73319,75822,46122,56420,85320,18918,30717,44319,76419,918------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.2%191,686195,969187,378175,124177,724178,355182,018179,228176,440172,557174,894170,693158,380155,017157,728155,521155,117150,027152,954155,703155,365
  Current Assets-5.9%60,56764,38855,29465,23663,84760,42460,97959,88953,76952,53351,23757,57845,89244,22645,27444,33341,79941,98746,03347,19445,438
    Cash Equivalents10.5%21,18319,17014,12711,35510,98310,46314,48717,60414,33212,67113,98518,96511,17415,53017,30516,24914,37614,73418,10716,05617,569
  Inventory0.6%12,88812,80912,48311,67511,43710,99010,38710,38710,1009,9529,3449,5999,4248,8689,0209,1739,2639,0868,5998,6788,810
  Net PPE2.0%20,57620,17419,80318,15218,35418,70118,96218,47818,63218,36718,76617,85517,59817,40117,65817,04817,24817,00017,03516,62916,632
  Goodwill-0.3%45,44045,57545,23133,38334,16634,93535,24635,56935,81920036,3931,20033,8901,20033,63933,29133,6612,00030,45330,7026,161
Liabilities-7.9%115,277125,100110,574100,525101,367103,646107,995108,956106,860106,723111,616106,22095,40293,72398,25797,31194,33291,07293,20291,07792,476
  Current Liabilities-10.3%54,17060,37355,80245,54344,82143,39045,22644,56138,72140,93242,49338,84736,77233,68935,96435,16231,35329,11131,23027,43727,488
  Short Term Borrowings-34.9%11,70117,97912,7714,4244,3054,2973,7663,7983,1733,3502,6315,0785,3322,1901,2022,2991,7191,7082,7961,7732,678
    LT Debt, Non Current-2.9%33,90134,92826,88827,60328,29228,85129,98530,13030,31030,26332,63532,68025,06225,39326,49426,91927,69927,66027,68429,48029,405
Shareholder's Equity6.0%75,14970,86976,80474,59976,35774,70974,02370,27269,58065,83463,27864,47362,97861,29459,47158,21060,78558,95559,75264,62662,889
  Retained Earnings3.9%129,381124,558128,345127,917126,216124,380123,060121,092120,154116,508113,890114,831113,898112,901110,659109,242109,809106,650106,216107,617106,123
Accumulated Depreciation1.5%30,64230,19329,45028,52928,79029,00128,71728,86928,56928,06328,03827,30726,45825,84625,67425,57725,65725,26224,81624,89124,661
Shares Outstanding-0.3%2,5982,606-2,6282,6302,629-2,6332,6332,632-2,6332,6332,634-2,6352,6532,661-2,6832,682
Minority Interest-1,260--------------------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-6.8%19,07320,47221,19421,57623,58223,31523,41026,02126,11424,25223,53621,59120,73523,23123,41623,26222,00722,13822,20122,06222,056
  Share Based Compensation1.4%1,1821,1661,1381,1401,1181,1061,1351,0801,0771,0491,0051,0059949829779739709689781,0261,020
Cashflow From Investing-21.0%-6,559-5,422-12,371-13,334-14,352-12,132-8,683-11,226-13,326-20,429-20,825-14,266-11,092-5,358-6,194-2,622-5,246-3,659-3,167-5,900-2,811
Cashflow From Financing-225.8%-2,0781,652-8,871-14,007-12,289-13,307-14,047-16,255-9,852-6,930-6,120-4,548-12,637-16,814-18,015-20,332-19,916-18,056-18,510-15,658-14,250
  Buy Backs-7.4%7,4037,9956,0355,7113,9373,5953,4562,7812,8732,9483,2213,3264,4716,2516,74610,1288,9716,6305,8682,8752,715

JNJ Income Statement

2023-07-02
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jul. 02, 2023
Jul. 03, 2022
Jul. 02, 2023
Jul. 03, 2022
Income Statement [Abstract]    
Sales to customers$ 25,530$ 24,020$ 50,276$ 47,446
Sales to customers percent to sales100.00%100.00%100.00%100.00%
Cost of products sold$ 8,212$ 7,919$ 16,607$ 15,517
Cost of products sold percent to sales32.20%33.00%33.00%32.70%
Gross profit$ 17,318$ 16,101$ 33,669$ 31,929
Gross Profit Percent To Sales67.80%67.00%67.00%67.30%
Selling, marketing and administrative expenses$ 6,665$ 6,226$ 12,803$ 12,164
Selling marketing and administrative expenses percent to sales26.10%25.90%25.50%25.60%
Research and development expense$ 3,829$ 3,703$ 7,392$ 7,165
Research and development expense percent to sales15.00%15.40%14.70%15.10%
In-process research and development impairments  $ 49$ 610
In-process research and development percent to sales  0.10%1.30%
Interest income$ (369)$ (64)$ (604)$ (86)
Interest income percent to sales(1.50%)(0.30%)(1.20%)(0.20%)
Interest expense, net of portion capitalized$ 346$ 38$ 561$ 48
Interest expense, net of portion capitalized percent to sales1.40%0.20%1.10%0.10%
Other (income) expense, net*$ (60)[1]$ 273$ 7,168[2]$ 171
Other (income) expense, net percent to sales(0.20%)1.10%14.30%0.40%
Restructuring$ 145$ 85$ 275$ 155
Restructuring charge percent to sales0.50%0.40%0.50%0.30%
Earnings before provision for taxes on income$ 6,762$ 5,840$ 6,025$ 11,702
Earnings before provision for taxes on income percent to sales26.50%24.30%12.00%24.70%
Provision for taxes on income (Note 5)$ 1,618$ 1,026$ 949$ 1,739
Provision for taxes on income percent to sales6.40%4.30%1.90%3.70%
Net earnings$ 5,144$ 4,814$ 5,076$ 9,963
Net earnings percent to sales20.10%20.00%10.10%21.00%
NET EARNINGS PER SHARE    
Basic (per share)$ 1.98$ 1.83$ 1.95$ 3.79
Diluted (per share)$ 1.96$ 1.80$ 1.93$ 3.73
AVG. SHARES OUTSTANDING    
Basic (shares)2,598.42,629.62,601.92,629.4
Diluted (shares)2,625.72,667.92,630.72,669.2
[1]Fiscal second quarter of 2023 Other (income) expense, net includes $37 million related to the 10.4% non-controlling interest in Kenvue from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
[2]Fiscal six months of 2023 Other (income) expense, net includes $37 million related to the 10.4% non-controlling interest in Kenvue from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.

JNJ Balance Sheet

2023-07-02
Consolidated Balance Sheets - USD ($)
$ in Millions
Jul. 02, 2023
Jan. 01, 2023
Current assets:  
Cash and cash equivalents (Note 4)$ 21,183$ 14,127
Marketable securities7,3229,392
Accounts receivable, trade, less allowances $205 (2022, $203)16,77716,160
Inventories (Note 2)12,88812,483
Prepaid expenses and other2,3973,132
Total current assets60,56755,294
Property, plant and equipment at cost51,21849,253
Less: accumulated depreciation(30,642)(29,450)
Property, plant and equipment, net20,57619,803
Intangible assets, net (Note 3)46,24648,325
Goodwill (Note 3)45,44045,231
Deferred taxes on income (Note 5)8,7799,123
Other assets10,0789,602
Total assets191,686187,378
Current liabilities:  
Loans and notes payable11,70112,771
Accounts payable10,44311,703
Accrued liabilities10,60511,456
Accrued rebates, returns and promotions15,67214,417
Accrued compensation and employee related obligations3,0623,328
Accrued taxes on income (Note 5)2,6872,127
Total current liabilities54,17055,802
Long-term debt (Note 4)33,90126,888
Deferred taxes on income (Note 5)3,6276,374
Employee related obligations (Note 6)6,4616,767
Long-term taxes payable (Note 5)2,5364,306
Other liabilities14,58210,437
Total liabilities115,277110,574
Commitments and Contingencies (Note 11)
Shareholders’ equity:  
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)3,1203,120
Accumulated other comprehensive income (loss) (Note 7)(13,135)(12,967)
Retained earnings and Additional paid-in capital129,381128,345
Less: common stock held in treasury, at cost (521,700,000 and 506,246,000 shares)44,21741,694
Stockholders' Equity Attributable to Parent75,14976,804
Total Johnson & Johnson shareholders’ equity76,40976,804
Stockholders' Equity Attributable to Noncontrolling Interest1,2600
Total liabilities and shareholders’ equity$ 191,686$ 187,378
Joaquin Duato
65535
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.